113 results
8-K
EX-10.1
SYRE
Spyre Therapeutics Inc.
25 Apr 24
Unregistered Sales of Equity Securities
4:21pm
no responsibility for, and provides no assurance as to the reliability of, any other information that others may provide to the Stockholder.
(f
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
years, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms … in Switzerland. Earlier in his career, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
or directors of the Company having responsibility for the matter or matters that are the subject of the statement. With respect to any matters relating … responsibility in the Company’s favor with respect to any of the transactions contemplated by this Agreement or the process leading thereto, and the Purchasers
8-K
EX-10.1
ngfymqah8cz 1kg96r
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
hq3hl
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
gx8k14el5 cprstoj1wc
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
424B3
1dbtex
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-14.1
aa6797xkn0bx uy5
5 Feb 24
Entry into a Material Definitive Agreement
7:36am
S-8
EX-99.1
sio70qsi
22 Dec 23
Registration of securities for employees
5:00pm
S-8
EX-99.2
2hl88we x4xa6lfjdj
22 Dec 23
Registration of securities for employees
5:00pm